Black Rock Inc. Design Therapeutics, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,304,948 shares of DSGN stock, worth $13 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,304,948
Previous 2,274,191
1.35%
Holding current value
$13 Million
Previous $9.16 Million
15.75%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding DSGN
# of Institutions
102Shares Held
31MCall Options Held
2.3KPut Options Held
16.5K-
Sr One Capital Management, LP6.53MShares$36.7 Million11.88% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$23.7 Million3.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.89MShares$10.6 Million0.55% of portfolio
-
Baker Bros. Advisors LP New York, NY1.74MShares$9.8 Million0.1% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.6MShares$9 Million0.02% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $314M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...